Pfizer received FDA approval for its IBRANCE regimen, while analyst commentary included a price target cut from Bank of America and an upgrade from Royal Bank of Canada. Separately, Nike appointed David Denton as its next CFO.
3 reports, 2 independent
Updated Sep 10
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Pfizer received FDA approval for its IBRANCE regimen, while analyst commentary included a price target cut from Bank of America and an upgrade from Royal Bank of Canada. Separately, Nike appointed David Denton as its next CFO.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Denton moves from Pfizer to Nike as CFO; UBS also monitoring Nike sales.1 source
Pfizer received FDA approval for IBRANCE; BoA cut price target; RBC upgraded shares; Nike appointed new CFO.1 source
Keep exploring
The entities involved
-
Pfizer
American multinational pharmaceutical and biotechnology corporation
-
Seagen
American biotechnology company
Nothing else this week.
-
Bank of America
American multinational banking and financial services corporation
Related events
- FDA and Pfizer are seeking regulatory approval for their products.
- Pfizer is jointly marketing the drug Eliquis.
- The FDA suspended Pfizer's C&F Depot license.
- FDA granted approval for Pfizer's updated vaccine on September 2, 2025.
- MarketBeat is providing analyst ratings and tracking the competitive landscape between healthcare companies Pfizer and Lyra Therapeutics.